|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1992-1-27
|
|
pubmed:abstractText |
Camptothecin-11 (CPT-11) is a new semisynthetic derivative of CPT, and has been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity in murine tumors. To evaluate the effectiveness of CPT-11 in patients with non-small-cell lung cancer (NSCLC), a phase II study was conducted between April 1989 and February 1990.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
16-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1309380-Adult,
pubmed-meshheading:1309380-Aged,
pubmed-meshheading:1309380-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:1309380-Camptothecin,
pubmed-meshheading:1309380-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:1309380-Diarrhea,
pubmed-meshheading:1309380-Drug Evaluation,
pubmed-meshheading:1309380-Female,
pubmed-meshheading:1309380-Humans,
pubmed-meshheading:1309380-Infusions, Intravenous,
pubmed-meshheading:1309380-Leukopenia,
pubmed-meshheading:1309380-Lung Neoplasms,
pubmed-meshheading:1309380-Male,
pubmed-meshheading:1309380-Middle Aged
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
|
|
pubmed:affiliation |
CPT-II Lung Cancer Study Group, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
